Evidence for acetylsalicylic acid (aspirin) in the prevention of preeclampsia: a narrative review

Descripción del Articulo

Objective: To describe the methods used to predict preeclampsia and how to preventit using low-dose acetylsalicylic acid (aspirin) according to the recommendationsof the main obstetrics and gynecology organizations. Methodology: We searchedPubMed and Cochrane Library from January 1, 2020, to May 1,...

Descripción completa

Detalles Bibliográficos
Autor: Vigil-De Gracia, Paulino
Formato: artículo
Fecha de Publicación:2022
Institución:Sociedad Peruana de Obstetricia y Ginecología
Repositorio:Revista Peruana de Ginecología y Obstetricia
Lenguaje:español
inglés
OAI Identifier:oai:ginecologiayobstetricia.pe:article/2453
Enlace del recurso:https://ginecologiayobstetricia.pe/index.php/RPGO/article/view/2453
Nivel de acceso:acceso abierto
Materia:Preeclampsia
prevención
predicción
Doppler
Aspirina
Pre-eclampsia
prevention
prediction
Doppler effect
Aspirin
id REVSPOG_496f1a7c558c0545e06e8ab719d3f6ae
oai_identifier_str oai:ginecologiayobstetricia.pe:article/2453
network_acronym_str REVSPOG
network_name_str Revista Peruana de Ginecología y Obstetricia
repository_id_str .
dc.title.none.fl_str_mv Evidence for acetylsalicylic acid (aspirin) in the prevention of preeclampsia: a narrative review
Evidencias del ácido acetilsalicílico (aspirina) en la prevención de la preeclampsia: revisión narrativa
title Evidence for acetylsalicylic acid (aspirin) in the prevention of preeclampsia: a narrative review
spellingShingle Evidence for acetylsalicylic acid (aspirin) in the prevention of preeclampsia: a narrative review
Vigil-De Gracia, Paulino
Preeclampsia
prevención
predicción
Doppler
Aspirina
Pre-eclampsia
prevention
prediction
Doppler effect
Aspirin
title_short Evidence for acetylsalicylic acid (aspirin) in the prevention of preeclampsia: a narrative review
title_full Evidence for acetylsalicylic acid (aspirin) in the prevention of preeclampsia: a narrative review
title_fullStr Evidence for acetylsalicylic acid (aspirin) in the prevention of preeclampsia: a narrative review
title_full_unstemmed Evidence for acetylsalicylic acid (aspirin) in the prevention of preeclampsia: a narrative review
title_sort Evidence for acetylsalicylic acid (aspirin) in the prevention of preeclampsia: a narrative review
dc.creator.none.fl_str_mv Vigil-De Gracia, Paulino
author Vigil-De Gracia, Paulino
author_facet Vigil-De Gracia, Paulino
author_role author
dc.subject.none.fl_str_mv Preeclampsia
prevención
predicción
Doppler
Aspirina
Pre-eclampsia
prevention
prediction
Doppler effect
Aspirin
topic Preeclampsia
prevención
predicción
Doppler
Aspirina
Pre-eclampsia
prevention
prediction
Doppler effect
Aspirin
description Objective: To describe the methods used to predict preeclampsia and how to preventit using low-dose acetylsalicylic acid (aspirin) according to the recommendationsof the main obstetrics and gynecology organizations. Methodology: We searchedPubMed and Cochrane Library from January 1, 2020, to May 1, 2022, using theterms “pre-eclampsia”, “hypertensive disorders in pregnancy” and “hypertensionand pregnancy”. We focused on the analyses and recommendations from the mostrecognized international obstetrics and gynecology organizations, independent ofthe original language. Results: For the prediction of preeclampsia, two strategies areused that aim to find the population at highest risk based on: 1) clinical findingsof risk for pre-pregnancy or pregnancy conditions, and 2) a multi-factor algorithmthat includes clinical findings, blood pressure, biomarker and uterine artery Doppler.Using both strategies, variable effectiveness of aspirin in preventing preeclampsiais found. The most effective dose range between 50-150 mg, with 81 mg being themost recommended at present. The dose of 150 mg per day has shown effectivenessin preeclampsia far from term; however, it is considered to have more side effects.Conclusions: The most prestigious and recognized obstetrics and gynecologyand health organizations recommend low-dose aspirin to prevent preeclampsia,preferably at the beginning of the second trimester of pregnancy and maintaineduntil 36-37 weeks.
publishDate 2022
dc.date.none.fl_str_mv 2022-12-20
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://ginecologiayobstetricia.pe/index.php/RPGO/article/view/2453
10.31403/rpgo.v68i2453
url https://ginecologiayobstetricia.pe/index.php/RPGO/article/view/2453
identifier_str_mv 10.31403/rpgo.v68i2453
dc.language.none.fl_str_mv spa
eng
language spa
eng
dc.relation.none.fl_str_mv https://ginecologiayobstetricia.pe/index.php/RPGO/article/view/2453/2691
https://ginecologiayobstetricia.pe/index.php/RPGO/article/view/2453/2692
dc.rights.none.fl_str_mv Derechos de autor 2022 Paulino Vigil-De Gracia
https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Derechos de autor 2022 Paulino Vigil-De Gracia
https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Sociedad Peruana de Obstetricia y Ginecología
publisher.none.fl_str_mv Sociedad Peruana de Obstetricia y Ginecología
dc.source.none.fl_str_mv The Peruvian Journal of Gynecology and Obstetrics ; Vol. 68 No. 4 (2022)
Revista Peruana de Ginecología y Obstetricia; Vol. 68 Núm. 4 (2022)
2304-5132
2304-5124
reponame:Revista Peruana de Ginecología y Obstetricia
instname:Sociedad Peruana de Obstetricia y Ginecología
instacron:SPOG
instname_str Sociedad Peruana de Obstetricia y Ginecología
instacron_str SPOG
institution SPOG
reponame_str Revista Peruana de Ginecología y Obstetricia
collection Revista Peruana de Ginecología y Obstetricia
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1868078737103257600
spelling Evidence for acetylsalicylic acid (aspirin) in the prevention of preeclampsia: a narrative reviewEvidencias del ácido acetilsalicílico (aspirina) en la prevención de la preeclampsia: revisión narrativaVigil-De Gracia, PaulinoPreeclampsiaprevenciónpredicciónDopplerAspirinaPre-eclampsiapreventionpredictionDoppler effectAspirinObjective: To describe the methods used to predict preeclampsia and how to preventit using low-dose acetylsalicylic acid (aspirin) according to the recommendationsof the main obstetrics and gynecology organizations. Methodology: We searchedPubMed and Cochrane Library from January 1, 2020, to May 1, 2022, using theterms “pre-eclampsia”, “hypertensive disorders in pregnancy” and “hypertensionand pregnancy”. We focused on the analyses and recommendations from the mostrecognized international obstetrics and gynecology organizations, independent ofthe original language. Results: For the prediction of preeclampsia, two strategies areused that aim to find the population at highest risk based on: 1) clinical findingsof risk for pre-pregnancy or pregnancy conditions, and 2) a multi-factor algorithmthat includes clinical findings, blood pressure, biomarker and uterine artery Doppler.Using both strategies, variable effectiveness of aspirin in preventing preeclampsiais found. The most effective dose range between 50-150 mg, with 81 mg being themost recommended at present. The dose of 150 mg per day has shown effectivenessin preeclampsia far from term; however, it is considered to have more side effects.Conclusions: The most prestigious and recognized obstetrics and gynecologyand health organizations recommend low-dose aspirin to prevent preeclampsia,preferably at the beginning of the second trimester of pregnancy and maintaineduntil 36-37 weeks.Objetivo. Describir los métodos usados para predecir preeclampsia y cómo prevenirla usando ácido acetilsalicílico (aspirina) a dosis bajas de acuerdo con las recomendaciones de las principales organizaciones de ginecología y obstetricia. Metodología. Se realizaron búsquedas en PubMed y Cochrane Library desde el 1 de enero de 2020 al 1 de mayo de 2022, con los términos “pre-eclampsia”, “trastornos hipertensivos en el embarazo” e “hipertensión y embarazo”. Nos enfocamos en los análisis y recomendaciones de las más reconocidas organizaciones internacionales de ginecología y obstetricia, independiente del idioma original. Resultados. Para la predicción de preeclampsia se usan dos estrategias que pretenden encontrar la población con más riesgo: 1) basada en hallazgos clínicos de riesgo por condiciones antes del embarazo o propias del embarazo, y 2) un algoritmo de múltiples factores que incluye hallazgos clínicos, presión arterial, biomarcador y Doppler de arteria uterina. Usando ambas estrategias se muestra efectividad variable de la aspirina en prevenir la preeclampsia. Se considera las dosis más efectivas entre 50 y 150 mg, siendo 81 mg la más recomendada en la actualidad. La dosis de 150 mg por día ha mostrado efectividad en la preeclampsia lejos del término; sin embargo, se considera que tiene más efectos secundarios. Conclusiones. Las más prestigiosas y reconocidas organizaciones de ginecología y obstetricia y de salud recomiendan aspirina a dosis bajas para prevenir la preeclampsia, preferiblemente al iniciar el segundo trimestre de gestación y mantenerla hasta las 36 a 37 semanas.Sociedad Peruana de Obstetricia y Ginecología2022-12-20info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttps://ginecologiayobstetricia.pe/index.php/RPGO/article/view/245310.31403/rpgo.v68i2453The Peruvian Journal of Gynecology and Obstetrics ; Vol. 68 No. 4 (2022)Revista Peruana de Ginecología y Obstetricia; Vol. 68 Núm. 4 (2022)2304-51322304-5124reponame:Revista Peruana de Ginecología y Obstetriciainstname:Sociedad Peruana de Obstetricia y Ginecologíainstacron:SPOGspaenghttps://ginecologiayobstetricia.pe/index.php/RPGO/article/view/2453/2691https://ginecologiayobstetricia.pe/index.php/RPGO/article/view/2453/2692Derechos de autor 2022 Paulino Vigil-De Graciahttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessoai:ginecologiayobstetricia.pe:article/24532026-01-12T15:21:29Z
score 13.411838
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).